Curing CML with imatinib—a dream come true?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://www.nature.com/articles/nrclinonc.2011.17.pdf
Reference10 articles.
1. Rousselot, P. et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58–60 (2007).
2. Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029–1035 (2010).
3. Ross, D. M. et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24, 1719–1724 (2010).
4. Bose, S., Deininger, M., Gora–Tybor, J., Goldman, J. M. & Melo, J. V. The presence of BCR-ABL fusion genes in leukocytes of normal individuals: implications for the assessment of minimal residual disease. Blood 92, 3362–3367 (1998).
5. Goldman, J. M. et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J. Clin. Oncol. 28, 1888–1895 (2010).
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Expression of GnT-III decreases chemoresistance via negatively regulating P-glycoprotein expression: Involvement of the TNFR2-NF-κB signaling pathway;Journal of Biological Chemistry;2023-04
2. Imatinib co-loaded targeted realgar nanocrystal for synergistic therapy of chronic myeloid leukemia;Journal of Controlled Release;2021-10
3. Discontinuation or Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response;Hematologic Malignancies;2021
4. Evaluation of Xpert ® BCR‐ABL Ultra for the confirmation of BCR‐ABL1 international scale conversion factors for the molecular monitoring of chronic myeloid leukaemia;International Journal of Laboratory Hematology;2020-09-29
5. Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence;International Journal of Hematology;2018-08-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3